Decibel Therapeutics IncNASDAQ:DBTX
- LAST PRICE4.3300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.0600/ 4
- Ask / Lots5.4900/ 47
- Open / Previous Close4.3000 / 4.3300
- Day Range
- 52 Week Range
- Volume25,672
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DBTX |
|---|---|---|
| 09:32 ET | 162 | 4.3 |
| 09:38 ET | 127 | 4.2016 |
| 09:41 ET | 100 | 4.4 |
| 10:03 ET | 400 | 4.37 |
| 10:08 ET | 200 | 4.25 |
| 10:14 ET | 200 | 4.25 |
| 10:35 ET | 266 | 4.25 |
| 10:55 ET | 100 | 4.275 |
| 11:22 ET | 266 | 4.25 |
| 11:36 ET | 400 | 4.28 |
| 11:42 ET | 630 | 4.25 |
| 11:45 ET | 5103 | 4.26 |
| 12:16 ET | 200 | 4.39 |
| 12:41 ET | 900 | 4.39 |
| 12:43 ET | 200 | 4.36 |
| 12:45 ET | 100 | 4.38 |
| 12:50 ET | 900 | 4.3873 |
| 12:52 ET | 1572 | 4.32 |
| 01:03 ET | 100 | 4.3202 |
| 01:06 ET | 300 | 4.32 |
| 01:30 ET | 200 | 4.35 |
| 01:32 ET | 200 | 4.35 |
| 02:06 ET | 100 | 4.31 |
| 02:18 ET | 875 | 4.33 |
| 02:20 ET | 240 | 4.31 |
| 02:22 ET | 500 | 4.3 |
| 02:29 ET | 300 | 4.32 |
| 03:03 ET | 100 | 4.355 |
| 03:25 ET | 188 | 4.36 |
| 03:38 ET | 1300 | 4.32 |
| 03:41 ET | 1817 | 4.27 |
| 03:45 ET | 200 | 4.27 |
| 03:48 ET | 200 | 4.31 |
| 03:50 ET | 100 | 4.3 |
| 03:52 ET | 500 | 4.305 |
| 03:57 ET | 100 | 4.335 |
| 03:59 ET | 1221 | 4.33 |
Aug 10, 2022
BRIEF-Decibel Therapeutics Inc - May Offer, Sell Shares Of Common Stock Of Up To $50 Million From Time To Time Through Jefferies, from 5:49PM ET on Wednesday Aug 10, 2022 by Thomson Reuters
5:49PM ET on Wednesday Aug 10, 2022 by Thomson ReutersBRIEF-Decibel Therapeutics Reports Second Quarter 2022 Financial Results And Corporate Update, from 4:31PM ET on Wednesday Aug 10, 2022 by Thomson Reuters
4:31PM ET on Wednesday Aug 10, 2022 by Thomson ReutersDecibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Update, from 4:30PM ET on Wednesday Aug 10, 2022 by GlobeNewswire
4:30PM ET on Wednesday Aug 10, 2022 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Decibel Therapeutics Inc | 107.1M | -2.0x | --- |
aTyr Pharma Inc | 104.6M | -2.0x | --- |
Dare Bioscience Inc | 104.2M | -2.7x | --- |
Rezolute Inc | 101.4M | -1.0x | --- |
Anebulo Pharmaceuticals Inc | 97.8M | -2.7x | --- |
NuCana PLC | 80.9M | -1.8x | --- |
Company Information
Decibel Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing transformative treatments for hearing and balance disorder. It is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The Company has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company’s pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.
Contact Information
- Headquarters
- 1325 Boylston Street, Suite 500BOSTON, MA, United States 02215
- Phone
- 617-370-8701
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- William Carson
- President, Chief Executive Officer, Director
- Laurence Reid
- Founder
- Gabriel Corfas
- Founder
- M. Charles Liberman
- Founder
- Ulrich Mueller
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $107.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 25.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.21 |
Book Value | $5.68 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
